News - Nordic Life Science Pipeline Inc. («Nordic») is proud to announce the launch of SQIN™ Body and SQIN ™ Hand & Foot, its first two cosmeceutical products to reach market. SQIN™ constitutes a unique line of skin products specifically designed and adapted for persistent and severe chronic dry skin problems found often in people suffering of paralysis or mobility impairment attributed to age, amputation, neurological and musculoskeletal problems or metabolic disorders.
News - The technology revolution that has taken hold in Québec City over the past few decades has spawned a number of life sciences success stories, paving the way for the development of a wide array of technologies in numerous fields. The life sciences sector alone employs nearly 6,000 people in Québec City and generates annual sales of over $1 billion, according to figures compiled by Québec International.c
News - Opsens Inc. is pleased to announce the reorganization of its corporate structure. Opsens' medical activities have taken a leading role in recent years, a result of the positive response to the performance of its products developed to measure Fractional Flow Reserve ("FFR"), their recent FDA approval which allows their marketing in the U.S., and the soon-to-come move into a state-of-the-art facility to increase manufacturing capacity and accommodate a growing number of employees. Opsens' FFR products are designed to optimize the diagnostic and guide treatment in patients with coronary heart disease.
News - The scientist who led the work to develop the Ebola drug ZMapp is going to be leaving the National Microbiology Laboratory in Winnipeg. Dr. Gary Kobinger is the lab's chief of special pathogens, heading a team that works on some of the world's worst disease threats. Kobinger will be vacating that position next June to become the director of the Centre for Research in Infectious Diseases at Laval University in Quebec City.
News - TSO3 Inc., an innovator in sterilization technology for medical devices in healthcare settings, announced that the Company has received purchase orders for multiple devices from the US. The orders are the result of the collaborative relationship between Getinge Infection Control, its sales and service provider, and the Company.
News - Opsens Inc. announced it has received Health Canada's approval to commercialize the OptoWire and OptoMonitor, its products developed to measure Fractional Flow Reserve ("FFR"). FFR is used to optimize the diagnosis and guide the treatment of patients with coronary heart disease.
News - TSO3 Inc. an innovator in sterilization technology for medical devices in healthcare settings, announced the formation of a wholly owned subsidiary: TSO3 Corporation, structured under the laws of the State of Delaware, and located in the State of South Carolina, USA. The new entity is being created to meet the demands of US customers for product, service and education.
News - handyem Inc. and FlowMetric Diagnostics Inc. announce their partnership centralized around the incorporation of handyem’s HPC-150 portable flow cytometer within FlowMetric Diagnostics’ , the Mo-POD™. This unprecedented model of mobile laboratory platform is presented at the BIO International Conference at the Pennsylvania Convention Center, Philadelphia from June 15th to 18th 2015.
News - Aeterna Zentaris Inc. and EMD Serono, Inc., the U.S. and Canadian biopharmaceutical businesses of Merck KGaA, Darmstadt, Germany, today announced the finalization of a promotional services agreement that will allow Aeterna Zentaris to promote Saizen® [somatropin (rDNA origin) for injection] to designated medical professionals in specified territories in the United States. Saizen® is a recombinant human Growth Hormone (r-hGH) registered in the U.S. for the treatment of growth hormone deficiency (GHD) in children and adults.
News - Opsens inc. is pleased to announce the first use of the OptoWire and OptoMonitor, its products to measure Fractional Flow Reserve ("FFR"), by Dr. Nico Pijls in Eindhoven, the Netherlands. Opsens' FFR products are designed to optimize the diagnosis and guide the treatment of patients with coronary heart disease.